Protein kinase C inhibits insulin-induced Akt activation in vascular smooth muscle cells

E D Motley1, S M Kabir, K Eguchi

  • 1Department of Anatomy & Physiology, Meharry Medical College, Nashville, TN 37208, USA. emotley@mmc.edu

Insights

Protein kinase C (PKC) activation inhibits insulin signaling in blood vessels. This finding suggests PKC plays a role in developing cardiovascular disease and insulin resistance.

Area of Science:

  • Vascular Biology
  • Endocrinology
  • Biochemistry

Background:

  • Hyperglycemia-induced Protein Kinase C (PKC) activation is linked to diabetes-related tissue damage.
  • Akt is a key mediator of insulin's biological effects.
  • Vascular insulin resistance contributes to cardiovascular disease pathogenesis.

Purpose of the Study:

  • To investigate the inhibitory effect of PKC on insulin-induced Akt activation in vascular smooth muscle cells (VSMCs).
  • To determine if PKC-mediated inhibition of Akt contributes to vascular insulin resistance and cardiovascular disease.

Main Methods:

  • Used cultured rat aortic VSMCs.
  • Measured Akt activation via immunoblotting with a phospho-Akt antibody (Ser473).
  • Utilized a PKC activator (phorbol 12-myristate 13-acetate, PMA) and a PKC inhibitor (G06983).

Main Results:

  • PMA inhibited insulin-stimulated Akt phosphorylation in VSMCs.
  • PMA did not affect platelet-derived growth factor (PDGF)-induced Akt activation.
  • The PKC inhibitor G06983 reversed the inhibitory effect of PMA on insulin-induced Akt phosphorylation.
  • PMA reduced insulin-induced tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1).

Conclusions:

  • PKC acts as a significant negative regulator of insulin signaling in the vasculature.
  • PKC's role in inhibiting insulin signaling is implicated in the development of insulin resistance within cardiovascular disease.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...